Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Scott Wendell Smith is active.

Publication


Featured researches published by Scott Wendell Smith.


Pharmaceutical Development and Technology | 2002

Hydrolysis in pharmaceutical formulations.

Kenneth C. Waterman; Roger Christopher Adami; Karen M. Alsante; Amy S. Antipas; Dan R. Arenson; Rebecca Carrier; Jinyang Hong; Margaret S. Landis; Franco Lombardo; Jaymin C. Shah; Evgenyi Y. Shalaev; Scott Wendell Smith; Hai Wang

This literature review presents hydrolysis of active pharmaceutical ingredients as well as the effects on dosage form stability due to hydrolysis of excipients. Mechanisms and measurement methods are discussed and recommendations for formulation stabilization are listed.


Journal of Pharmaceutical Sciences | 2005

Kinetics and Mechanism of the Reaction of Cysteine and Hydrogen Peroxide in Aqueous Solution

Dayong Luo; Scott Wendell Smith; Bradley D. Anderson


Trends in Analytical Chemistry | 2013

Physical stability of pharmaceutical formulations: solid-state characterization of amorphous dispersions

Yushen Guo; Evgenyi Y. Shalaev; Scott Wendell Smith


Archive | 2002

Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene

Mary T. am Ende; Michael Christopher Roy; Scott Wendell Smith; Kenneth C. Waterman; Sara Kristen Moses


Archive | 2006

Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Dwayne Thomas Friesen; Douglas Alan Lorenz; Scott Wendell Smith


Archive | 2004

Compositions comprising an HIV protease inhibitor

Scott Wendell Smith; Dwayne Thomas Friesen; Douglas Alan Lorenz; David Keith Lyon; Rodney James Ketner; James Blair West


Archive | 2002

Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene

Ende Mary Tanya Am; Michael Christopher Roy; Scott Wendell Smith; Kenneth C. Waterman; Sara Kristen Moses; Ernest Shing Quan


Archive | 2002

Compositions pharmaceutiques de 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene

Ende Mary Tanya Am; Michael Christopher Roy; Scott Wendell Smith; Kenneth C. Waterman; Sara Kristen Moses; Ernest Shing Quan


Archive | 2002

Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene

Ende Mary Tanya Am; Michael Christopher Roy; Scott Wendell Smith; Kenneth C. Waterman; Sara Kristen Moses; Ernest Shing Quan


Archive | 2002

Pharmaceutical compositions Oral controlled release of 5,8,14-triazatetracyclo (10.3.1.0 (2,11) .0 (4,9) -hexadeca-2 (11) 3,5,7,9-pentaene.

Ende Mary Tanya Am; Sara Kristen Moses; Ernest Shing Quan; Michael Christopher Roy; Scott Wendell Smith; Kenneth C. Waterman

Collaboration


Dive into the Scott Wendell Smith's collaboration.

Researchain Logo
Decentralizing Knowledge